ARS Pharmaceuticals, Inc. has recently released its 10-K report, providing a detailed insight into the company's financial and operational performance. The San Diego-based biopharmaceutical company focuses on developing and commercializing treatments for severe allergic reactions. Its flagship product, neffy, is a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis.
The company's 10-K report highlights its significant achievements, including the FDA and European Commission approvals for neffy, making it the first and only needle-free epinephrine product with approvals in the U.K., Japan, Australia, and China. The report also outlines the company's strategies for market penetration, including its sales force composition, collaborations with healthcare professionals, and engagement with payors.
Financially, the report reveals that as of December 31, 2025, ARS Pharmaceuticals had cash, cash equivalents, and short-term investments of $245.0 million. However, the company reported a net loss of $171.3 million for the year ended December 31, 2025, and an accumulated deficit of $294.6 million as of the same date. The report also discusses the company's plans to finance its operations through various means, including equity offerings, debt financings, and collaborations.
Additionally, the report provides insights into the company's revenues, cost of goods sold, and research and development expenses. It details the fluctuations in product revenues and the costs associated with manufacturing neffy for commercial sale, including third-party manufacturing costs, raw material and component costs, and inventory write-offs.
Today the company's shares have moved -4.15% to a price of $10.63. For the full picture, make sure to review ARS Pharmaceuticals's 10-K report.
